Trial Profile
An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Azathioprine; Leflunomide; Methotrexate; Sulfasalazine
- Indications Adult-onset Still's disease
- Focus Therapeutic Use
- Acronyms AOSD Study 05
- 01 Aug 2012 Results published in The Journal of Rheumatology.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed based on results published in The Journal of Rheumatology.
- 19 Jun 2010 Results presented at the 11th Annual Congress of the European League Against Rheumatism